Katherine E. Wolski
#150,935
Most Influential Person Now
Katherine E. Wolski's AcademicInfluence.com Rankings
Katherine E. Wolskimathematics Degrees
Mathematics
#6989
World Rank
#9588
Historical Rank
Applied Mathematics
#284
World Rank
#309
Historical Rank
Statistics
#733
World Rank
#820
Historical Rank
Measure Theory
#1781
World Rank
#2183
Historical Rank
Download Badge
Mathematics
Katherine E. Wolski's Degrees
- PhD Biostatistics University of California, Berkeley
- Masters Statistics Stanford University
- Bachelors Mathematics University of California, Berkeley
Similar Degrees You Can Earn
Why Is Katherine E. Wolski Influential?
(Suggest an Edit or Addition)Katherine E. Wolski's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. (2007) (4608)
- Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. (2006) (1952)
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes (2017) (1559)
- Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. (2014) (1503)
- Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. (2007) (1188)
- Bariatric surgery versus intensive medical therapy in obese patients with diabetes. (2012) (933)
- Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (2008) (836)
- Effect of two intensive statin regimens on progression of coronary disease. (2011) (744)
- Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. (2010) (579)
- Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. (2007) (573)
- Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. (2005) (560)
- Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease (2017) (462)
- Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. (2008) (413)
- Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. (2010) (397)
- Abciximab reduces mortality in diabetics following percutaneous coronary intervention. (2000) (352)
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. (2016) (331)
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. (2020) (331)
- Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. (2008) (322)
- Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study (2001) (318)
- Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials (2001) (237)
- Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. (2019) (226)
- Fenestrated and branched endovascular aneurysm repair outcomes for type II and III thoracoabdominal aortic aneurysms. (2016) (202)
- Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. (2006) (191)
- Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). (2002) (183)
- Twelve-year results of fenestrated endografts for juxtarenal and group IV thoracoabdominal aneurysms. (2015) (182)
- Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes (2013) (179)
- Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. (2011) (170)
- Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. (2013) (164)
- Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention (2004) (162)
- Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection (2021) (160)
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. (2016) (157)
- Determinants of Arterial Wall Remodeling During Lipid-Lowering Therapy: Serial Intravascular Ultrasound Observations From the Reversal of Atherosclerosis With Aggressive Lipid Lowering Therapy (REVERSAL) Trial (2006) (151)
- Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial (2018) (150)
- Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound. (2012) (146)
- Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. (2010) (144)
- Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. (2014) (143)
- The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. (2010) (139)
- Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. (2002) (134)
- Coronary artery calcification and changes in atheroma burden in response to established medical therapies. (2007) (134)
- Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. (2007) (129)
- Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. (2009) (123)
- Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events: Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial (2001) (117)
- -Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials (2007) (113)
- Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival (2003) (106)
- Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruct (2011) (103)
- Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial (2018) (101)
- Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. (2014) (95)
- Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). (2005) (93)
- Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial (2016) (92)
- Peripheral arterial disease and progression of coronary atherosclerosis. (2010) (90)
- Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. (2000) (85)
- Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial* (2002) (83)
- Rate of progression of coronary atherosclerotic plaque in women. (2007) (83)
- Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up. (2010) (81)
- Effect of Evolocumab on Coronary Plaque Composition. (2018) (81)
- Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. (2000) (77)
- Two‐year outcomes on bone density and fracture incidence in patients with T2DM randomized to bariatric surgery versus intensive medical therapy (2015) (76)
- Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). (2003) (72)
- Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. (2009) (71)
- Factors underlying regression of coronary atheroma with potent statin therapy. (2013) (67)
- Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance. (2020) (61)
- Atheroma Progression in Hyporesponders to Statin Therapy (2015) (61)
- Impact of Mitral Regurgitation on Reverse Remodeling and Outcome in Patients Undergoing Cardiac Resynchronization Therapy (2012) (57)
- A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart Transplantation: The Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) Trial (2011) (56)
- Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. (2022) (56)
- An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality (2010) (56)
- Improved acylated ghrelin suppression at 2 years in obese patients with type 2 diabetes: effects of bariatric surgery vs standard medical therapy (2014) (54)
- Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial (2021) (51)
- Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound. (2014) (47)
- Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. (2003) (47)
- Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. (2007) (46)
- Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque: A Combined Pathological and In Vivo Study (2015) (45)
- Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events. (2013) (44)
- Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk (2005) (43)
- Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. (2006) (42)
- Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. (2005) (41)
- Predicting 10-Year Risk of End-Organ Complications of Type 2 Diabetes With and Without Metabolic Surgery: A Machine Learning Approach (2020) (40)
- Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial. (2020) (40)
- ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study (2018) (39)
- Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. (2004) (39)
- Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial. (2021) (39)
- Confirmation of the Intracoronary Near-Infrared Spectroscopy Threshold of Lipid-Rich Plaques That Underlie ST-Segment–Elevation Myocardial Infarction (2016) (38)
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. (2022) (38)
- Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial (2018) (35)
- Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials. (2009) (35)
- Comparison of rates of progression of coronary atherosclerosis in patients with diabetes mellitus versus those with the metabolic syndrome. (2010) (34)
- Validation of a method for determination of the ankle-brachial index in the seated position. (2008) (33)
- Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis (2018) (32)
- Late Outcomes After Carotid Artery Stenting Versus Carotid Endarterectomy: Insights From a Propensity-Matched Analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry (2010) (32)
- Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. (2018) (32)
- Bivalirudin vs Heparin in Percutaneous Coronary Intervention: A Pooled Analysis (2005) (31)
- Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus (2013) (30)
- The benefit of abciximab in percutaneous coronary revascularization is not device-specific. (2000) (30)
- Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial. (1999) (30)
- Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes (2015) (29)
- Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. (2006) (29)
- Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates < or = 60 versus > 60 ml/min/1.73 m(2): a meta-analysis of intravascular ultrasound studies. (2007) (28)
- Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity: Comparison of Gastric Bypass, Sleeve Gastrectomy, and Usual Care (2021) (28)
- Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation (2021) (26)
- ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy). (2004) (24)
- Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation (2020) (23)
- Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. (2014) (23)
- A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart TransplantationClinical Perspective (2011) (20)
- Atrial fibrillation, progression of coronary atherosclerosis and myocardial infarction (2017) (20)
- Impact of alterations in target vessel curvature on branch durability after endovascular repair of thoracoabdominal aortic aneurysms. (2016) (20)
- Association of Weight Loss Achieved Through Metabolic Surgery With Risk and Severity of COVID-19 Infection. (2021) (19)
- How Much Weight Loss is Required for Cardiovascular Benefits? Insights From a Metabolic Surgery Matched-cohort Study. (2020) (19)
- Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). (2022) (18)
- Study Design and Rationale of VALOR-HCM: Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy who are Eligible for Septal Reduction Therapy. (2021) (17)
- Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial (2018) (17)
- Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax t (2006) (17)
- Cardiovascular Biomarkers After Metabolic Surgery Versus Medical Therapy for Diabetes. (2019) (15)
- HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. (2016) (15)
- Plaque progression in coronary arteries with minimal luminal obstruction in intravascular ultrasound atherosclerosis trials. (2010) (15)
- Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. (2001) (14)
- Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial (2020) (13)
- Optimal Activated Clotting Time During Percutaneous Coronary Intervention (2001) (13)
- Effects of Long-term Testosterone Treatment on Cardiovascular Outcomes in Men with Hypogonadism: Rationale and Design of the TRAVERSE Study (2021) (13)
- Systemic connective tissue features in women with fibromuscular dysplasia (2015) (12)
- The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE (2019) (12)
- IMPACT OF WEIGHT LOSS TRAJECTORY FOLLOWING RANDOMIZATION TO BARIATRIC SURGERY ON LONG-TERM DIABETES GLYCEMIC AND CARDIOMETABOLIC PARAMETERS. (2019) (12)
- Dynamic Assessment of Pulmonary Artery Pulsatility Index Provides Incremental Risk Assessment for Early Right Ventricular Failure after Left Ventricular Assist Device. (2021) (10)
- Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. (2002) (10)
- Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial (2019) (9)
- Progression of coronary atherosclerosis in African-American patients. (2013) (7)
- Association of Serum Lipoprotein (a) Levels and Coronary Atheroma Volume by Intravascular Ultrasound (2019) (7)
- Technology-Assisted Self-Selection of Candidates for Nonprescription Statin Therapy. (2021) (6)
- Patient-reported Outcomes After Metabolic Surgery Versus Medical Therapy for Diabetes (2021) (6)
- Downstream coronary effects of drug-eluting stents. (2011) (6)
- Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy (2019) (6)
- Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial (2019) (5)
- Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study (2022) (5)
- The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial (2018) (5)
- Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease (2022) (5)
- Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices. (2021) (5)
- Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks (2022) (4)
- Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. (2018) (4)
- Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial). (2019) (4)
- Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention. (2006) (4)
- Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. (2016) (3)
- Cardiovascular Biomarkers after Metabolic Surgery versus Medical Therapy for Diabetes: Insights from the STAMPEDE Trial (2018) (3)
- Abstract 1391: Atherogenic Dyslipidemia Predicts Accelerated Progression of Atherosclerosis in Patients with Coronary Artery Disease (2007) (3)
- Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]. (1999) (2)
- Pioglitazone vs Glimepiride in the PERISCOPE Trial—Reply (2008) (2)
- Abstract 20401: Cardiorenal Risks of Celecoxib, Naproxen or Ibuprofen in Arthritis Patients : A Sub-Anaylsis From the PRECISION Trial (2017) (2)
- Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial (2019) (2)
- REGRESSION OF CORONARY ATHEROMA VOLUME IN PATIENTS RECEIVING HIGH DOSE STATIN THERAPY: ANALYSIS OF THE SATURN STUDY (2012) (2)
- EFFECTS OF AN APOLIPOPROTEIN A-1 INDUCER ON PROGRESSION OF CORONARY ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ELEVATED INFLAMMATORY MARKERS (2014) (2)
- Abstract 17400: Lipoprotein(a) is a Determinant of Residual Cardiovascular Risk in the Setting of Optimal LDL-C in Statin-Treated Patients With Atherosclerotic Cardiovascular Disease (2017) (2)
- Abstract 4418: Carotid Endarterectomy versus Carotid Artery Stenting: Insights From a Propensity Matched Analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry (2009) (2)
- Abstract 17856: Effect of Aspirin on the Cardiovascular, Gastrointestinal, and Renal Safety of Celecoxib, Naproxen, or Ibuprofen (2017) (1)
- Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION (2020) (1)
- Abstract 10453: Impact of Diabetes Duration on Atheroma Progression in Diabetic Patients with Coronary Artery Disease: Insights From Serial Intravascular Ultrasound (2011) (1)
- ELEVATED LEVELS OF THE NEUTROPHIL TO LYMPHOCYTE RATIO PREDICTS INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN HIGH RISK PATIENTS: INSIGHTS FROM ACCELERATE (2018) (1)
- Coronary Atheroma Regression With Evolocumab in Stable and Unstable Coronary Syndromes. (2022) (1)
- Erratum. Predicting 10-Year Risk of End-Organ Complications of Type 2 Diabetes With and Without Metabolic Surgery: A Machine Learning Approach. Diabetes Care 2020;43:852–859 (2020) (1)
- Cardiorenal Risk of Celecoxib compared to Naproxen, or Ibuprofen in Arthritis Patients: Insights from the PRECISION trial. (2022) (1)
- Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survival. (2003) (1)
- Gastrointestinal Events in Arthritis Patients at Increased Cardiovascular Risk Treated Chronically with Celecoxib, Naproxen or Ibuprofen: The Precision Randomized Controlled Trial (2017) (1)
- Questions Surround Safety of Rosiglitazone (2007) (1)
- IMPACT OF MULTIPLE RISK FACTOR INTERVENTION ON PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2011) (1)
- Abstract 13442: Aging, Risk Factors and Progression of Coronary Atherosclerosis (2010) (1)
- COMPARISON OF THE SAFETY OF CELECOXIB, IBUPROFEN, AND NAPROXEN IN PATIENTS WITHOUT ESTABLISHED CARDIOVASCULAR DISEASE (2019) (1)
- TCT-660 Multicenter Validation of a Near-infrared Spectroscopic Signature of Culprit Lesions Causing ST-segment Elevation Myocardial Infarction: The NIRSTEMI II Study (2013) (1)
- LARGER LIPID POOLS ASSOCIATE WITH FEATURES OF PLAQUE VULNERABILITY ON OPTICAL COHERENCE TOMOGRAPHY (2013) (1)
- Abstract 1195: Proatherogenic Impact of the ACAT Inhibitor Pactimibe in Patients with Coronary Artery Disease and Multiple Risk Factors: Insights from the ACTIVATE study (2006) (1)
- IMPACT OF STATIN THERAPY ON PLAQUE MICROSTRUCTURES ON OPTICAL COHERENCE TOMOGRAPHY (2016) (0)
- Abstract 20126: CRP, Risk Factors and Major Adverse Cardiovascular Events: Insights From ACCELERATE (2017) (0)
- Analytical Issues Regarding Rosiglitazone Meta-analysis—Reply (2011) (0)
- Abstract 3724: Optimal Control of Both Lipids and Blood Pressure is Required for Maximal Regression of Coronary Atherosclerosis (2006) (0)
- Abstract 3779: Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering: Insights from the ASTEROID Trial (2006) (0)
- DOSE ESCALATION AND THE SAFETY OF CELECOXIB, IBUPROFEN, AND NAPROXEN: ANALYSIS OF THE PRECISION TRIAL (2018) (0)
- Improved outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery treated with combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition (2002) (0)
- Abstract 3727: Progression of Coronary Atherosclerosis: Do ACE Inhibitors Make a Difference? (2006) (0)
- GREATER PROGRESSION OF CORONARY ATHEROSCLEROSIS IN AFRICAN-AMERICAN PATIENTS DESPITE THE USE OF ESTABLISHED MEDICAL THERAPIES (2011) (0)
- Abstract 14913: Variable Effects on Lipid Transporting and Non-Lipid Transporting Functions of HDL in Young Patients With Chronic Inflammatory Arthritis (2013) (0)
- Abstract 10439: Natural History of Echolucent Plaque in Stable Patients with Coronary Artery Disease: Insights From Intravascular Ultrasound (2011) (0)
- 196 INCREASING CIRCULATING CONCENTRATION OF ALL HDL PARTICLE SUBCLASSES IN HYPER-RESPONDERS TO APOLIPOPROTEIN A-I INDUCTION: INSIGHTS FROM THE ASSERT STUDY (2011) (0)
- TCT-281 The Association Between Cholesterol Crystal And Features Of Plaque Vulnerability On Optical Coherence Tomography (2012) (0)
- 683: Core Lab Analysis of Intravascular Ultrasound Studies from the TICTAC Trial (Tacrolimus in Combination, Tacrolimus Alone Compared): Is There a Price To Pay for Monotherapy? (2009) (0)
- Anandamide as a Marker of Human Disease TotheEditor:IntheirResearchLetter,DrHabayebandcol- (2017) (0)
- The Association Between Cholesterol Crystal And Features Of Plaque Vulnerability On Optical Coherence Tomography (2016) (0)
- Abstract 20260: Impact of Glycemic Control on Residual Cardiovascular Risk in Diabetic Patients Treated With Statin Therapy (2017) (0)
- PRIOR CORONARY ARTERY BYPASS GRAFTING AND INCIDENT CARDIOVASCULAR EVENTS IN THE SETTING OF CONTEMPORARY MEDICAL THERAPY: INSIGHTS FROM ACCELERATE (2018) (0)
- Pioglitazone vs Glimepiride in the PERISCOPE Trial. Authors' reply (2008) (0)
- O040 Changes in plaque composition with a novel apolipoprotein A-I inducer: insights from the assure study (2014) (0)
- 542 Incidence of Coronary Artery Vasculopathy Has Decreased with Modern Immunosuppression: Insights from Clinical Trials in Organ Transplantation (2011) (0)
- Rimonabant and progression of atherosclerosis in obese persons - Reply (2008) (0)
- Baseline Characteristics of Patients With CAS Versus CEA Before and After Propensity Score Matching Parameter (2010) (0)
- INTERNATIONAL PROSPECTIVE VALIDATION OF AN INTRACORONARY NEAR–INFRARED SPECTROSCOPY SIGNATURE OF CULPRIT LESIONS IN ACUTE STEMI (2013) (0)
- BLOOD PRESSURE CONTROL AND ATHEROMA PROGRESSION IN DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE: INSIGHTS FROM INTRAVASCULAR ULTRASOUND (2012) (0)
- FACTORS INFLUENCING THE NATURAL HISTORY OF CORONARY ATHEROMA CALCIFICATION: INSIGHTS FROM SERIAL INTRAVASCULAR ULTRASOUND (2010) (0)
- Safety and Impact of Direct Left Atrial Pressure Monitoring in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation. (2020) (0)
- Abstract 15937: Abnormal Left Ventricular Conduction is Associated With Increased Cardiovascular Mortality Compared to Abnormal Right Ventricular or Normal Conduction: Insights From the Precision Trial (2017) (0)
- Abstract 623: Effect of High-intensity Statin Therapy on High-density Lipoprotein (HDL) Subfractions and Regression of Coronary Atheroma: The SATURN Trial (2016) (0)
- Abstract 21363: Improving Glycemic Control is Associated with A Beneficial Impact on Progression of Coronary Atherosclerosis: Insights From Intravascular Ultrasound (2010) (0)
- MILANO-PILOT: will infusing HDL mimetics containing apoA-imilano continue to regress coronary atherosclerosis in the modern era of intensive statin therapy? (2017) (0)
- Abstract 1558: Changes in Markers of Systemic Inflammation Predict Progression of Coronary Atherosclerosis in Patients With Abdominal Obesity (2009) (0)
- Lack of improvement in ST segment resolution after the combination treatment of abciximab with reteplase compared to reteplase alone for acute myocardial infarction: results from the GUSTO V-RESTART substudy (2002) (0)
- Abstract 17515: Factors Associated with Stent Thrombosis Causing ST- Segment Elevation Myocardial Infarction (2013) (0)
- Abstract 3479: Emerging Cardiovascular Risk Factors That Account For A Significant Portion Of Attributable Mortality Risk In Chronic Kidney Disease: A Precis Study. (2007) (0)
- Predictive value of 60-minute ST segment resolution in electrocardiogram after lytic therapy in patients with acute myocardial infarction: results from the GUSTO V-RESTART study (2002) (0)
- Unplanned HM3 Heart Failure-Related Hospitalizations: Reclassifying Post-Discharge Right Ventricular Failure. (2020) (0)
- The Relationship Between Coronary Arterial Plaque Burden and Lipid Pools: Histological Validation Using Near-Infrared Spectroscopy and Intravascular Ultrasound (2013) (0)
- MYOCARDIAL DEFORMATION ASSESSMENT PROVIDES SUPERIOR INCREMENTAL PROGNOSTIC RISK STRATIFICATION IN PATIENTS WITH CARDIAC AMYLOIDOSIS COMPARED TO LATE GADOLINIUM ENHANCEMENT (2023) (0)
- Abstract 3805: The Use of COX-2 Inhibitors and the Risk of Myocardial Infarction in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial (2006) (0)
- ACHIEVED LIPOPROTEIN LEVELS AND REGRESSION OF CORONARY ATHEROSCLEROSIS WITH HIGH DOSE STATIN THERAPY: INSIGHTS FROM SATURN (2012) (0)
- Rosiglitazone associated with increased risk of MI and cardiovascular- related death (2007) (0)
- Abstract 479: Juvenile Idiopathic Arthritis Does Not Impair ABCA-1 and SR-B1-Mediated Cholesterol Efflux Capacity (2012) (0)
- P5421Cardiorenal risk of celecoxib compared to naproxen, or ibuprofen in arthritis patients: a sub-analysis of the PRECISION trial (2018) (0)
- Abstract 1992: Evolution of the Pattern of Atherosclerosis Assessed by Intravascular Ultrasound in Women: A Substudy of the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) (2006) (0)
- PRE-IMPLANT LEFT VENTRICULAR SIZE BEST PREDICTS POOR CARDIAC POWER INDEX IN PATIENTS WITH HM3 SUPPORT (2020) (0)
- Abstract 1460: Clinical Predictors of Atherosclerosis Progression in Patients With Very Low Levels of LDL Cholesterol (2009) (0)
- Abstract: 1495 ATHEROSCLEROTIC PROGRESSION AND REMODELING IN ARTERIES WITH MINIMAL ANGIOGRAPHIC DISEASE (2009) (0)
- THE EFFECT OF HIGH–INTENSITY STATIN THERAPY ON CHANGES IN ATHEROMA COMPOSITION: INSIGHTS FROM SATURN (2013) (0)
- Abstract 13095: Regression of Left Main Coronary Arterial Atherosclerosis: Implications for Major Adverse Cardiovascular Events (2011) (0)
- Abstract 10446: Accelerated Progression of Coronary Atherosclerosis in Hyporesponders to Statin Therapy (2011) (0)
- Abstract 3726: Beta-Blockers and Progression of Coronary Atherosclerosis:A Meta-Analysis from Four Intravascular Ultrasound Trials (2006) (0)
- Abstract 13108: Intensive Multi-target Lipid Lowering and Progression of Coronary Atherosclerosis (2010) (0)
- P4473Baseline insulin levels are associated with need for revascularization among diabetic patients with high risk vascular disease: insights from the ACCELERATE trial (2018) (0)
- 176 ANTI-INFLAMMATORY EFFECTS OF A NOVEL INDUCER OF APOLIPOPROTEIN A-I SYNTHESIS: INSIGHTS FROM THE ASSERT STUDY (2011) (0)
- Implications of Early Hemodynamic Profiling after Continuous-Flow Left Ventricular Assist Device Implantation. (2020) (0)
- TCT-24 Combined Near-Infrared Spectroscopic and Intravascular Ultrasound Assessment Of Coronary Plaque Burden and Lipid Pools: Validation With Histology (2012) (0)
- CLINICAL PREDICTORS OF CARDIOVASCULAR OUTCOMES IN PATIENTS ON CELECOXIB, IBUPROFEN, AND NAPROXEN (2019) (0)
- Inhibition in Complex Atherosclerotic Lesions Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa (2013) (0)
- IMPROVEMENT IN MULTI-DOMAIN PATIENT-REPORTED OUTCOME SCORES WITH MAVACAMTEN TREATMENT IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INSIGHTS FROM THE VALOR-HCM STUDY (2023) (0)
- Abstract 4149: Regression of Coronary Atherosclerosis Following Intensive Risk Factor Modification in Patients With the Metabolic Syndrome (2006) (0)
- Abstract 15172: Quantitative Changes in High-Density Lipoprotein Underlie Impaired SR-B1 Mediated Efflux in Obese Individuals (2011) (0)
- SS2. Fenestrated and Branched Endovascular Aneurysm Repair (F/B-EVAR) Outcomes for Type II and III Thoracoabdominal Aortic Aneurysms (TAAAs) (2015) (0)
- 1226-P: Three Year Outcomes after Metabolic Surgery or Medical/Lifestyle Intervention: The ARMMS-T2D Trial (2021) (0)
- Abstract: P1386 LOWERING OF HBAIC IS ASSOCIATED WITH LESS PROGRESSION OF CORONARY ATHEROSCLEROSIS (2009) (0)
- Lipid-lowering drugs prescription of lipid-lowering drugs at hospital discharge following an acute coronary syndrome was associated with reduced short-term mortality (2001) (0)
- Abstract 4106: Effect of Obesity on Progression of Coronary Atherosclerosis: Observations from Four Intravascular Ultrasound Trials (2006) (0)
- TCT-245 Impact of Statin Therapy on Plaque Microstructures on Optical Coherence Tomography (2012) (0)
- Abstract 15752: Incidence of Silent Myocardial Infarction in a Major Cardiovascular Clinical Trial: Insights From the PRECISION Trial (2017) (0)
- Cerebral Blood Flow, Endothelial Function In Patients With Coronary Artery Disease And Arterial Hypertension Receiving Ivabradine In Combination With Perindopril (2014) (0)
- Abstract 13297: Temporal Changes in Management of Heart Transplant Recipients and Impact on Coronary Allograft Vasculopathy (2012) (0)
- Abstract 14775: Differential Responses of Atheroma Progression to Blood Pressure Lowering in Patients with and without Diabetes (2014) (0)
- THE DEGREE OF GLYCEMIC CONTROL IS ASSOCIATED WITH EXTENSIVE SUBCLINICAL ATHEROSCLEROSIS AND IMPAIRED SR-BI MEDIATED EFFLUX IN OBESE INDIVIDUALS (2012) (0)
- Spotty Calcification Associates with Coronary Plaque Microstructures In Vivo: Insights From Fourier-Domain Optical Coherence Tomography Analysis (2013) (0)
- ATRIAL FIBRILLATION IS NOT ASSOCIATED WITH INCREASED PROGRESSION OF CORONARY ATHEROSCLEROSIS: INSIGHTS FROM INTRAVASCULAR ULTRASOUND ATHEROSCLEROSIS TRIALS (2010) (0)
- Abstract 17446: Fasting Remnant Cholesterol Levels Predict Incident Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease: The ACCELERATE Trial (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Katherine E. Wolski?
Katherine E. Wolski is affiliated with the following schools:
